The subcommittee weighed several possible stage 3 requirements, such as using clinical decision support alerts for possible medication interactions and drug allergies and identifying patients’ preferences for receiving health information.
According to the report, the subcommittee also discussed whether future electronic health record systems should have the ability to upload data on drug interactions and automatically alert physicians to potentially dangerous medication combinations.
More Articles on Meaningful Use:
CMS Contractor to Begin Meaningful Use Audits
4 Actions to Achieve Meaningful Use While Preparing for Value-Based Care
Stage 3 Meaningful Use Draft Recommendations May Be Released in August
